A Phase 3 interventional study of Moxidex otic solution and Moxifloxacin otic solution in Acute Otitis Externa, sponsored by Alcon Research. Completed. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2012-12-03.
Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if an otic formulation is safe and effective for the treatment of acute otitis externa (AOE).
23 studies on the registry are indexed under Otitis Externa; 2 are open to participants now.
This study's enrollment of 990 is above the median of 100 across 20 interventional studies indexed under Otitis Externa.
Browse Otitis Externa studies →Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Moxidex otic solution
Drug: Moxidex otic solution · Device: Tympanostomy tubes
Moxifloxacin otic solution
Drug: Moxifloxacin otic solution · Device: Tympanostomy tubes
Dexamethasone phosphate otic solution
Drug: Dexamethasone phosphate otic solution · Device: Tympanostomy tubes
Drug pages: Moxifloxacin · Dexamethasone phosphate
4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
Clinical Cure
Time frame: Day 3
Clinical Cure
Time frame: Day 12
Microbiological Success
Time frame: Day 12
No study locations are listed for this record.
The record gives a start of Jun 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Moxifloxacin · Dexamethasone phosphate